Alnylam Pharmaceuticals Shares Drop 18% Despite Q3 Earnings Beat Due to Slowing US Sales
Alnylam Pharmaceuticals (ALNY) saw its stock price decline by approximately 18% during Thursday morning trading, despite reporting third-quarter financial results that exceeded analyst expectations for both revenue and earnings. The market reaction was driven by concerns regarding the deceleration of sales growth in the United States for two of its key hereditary transthyretin-mediated amyloidosis treatments. The slowdown specifically impacted Amvuttra (vutrisiran) and Onpattro (patisiran), which are central to the company's commercial portfolio. Despite the top and bottom-line beats, investors appear focused on the slowing momentum of these core products within the US market rather than the immediate quarterly performance.
Tickers: $ALNY
Topics: biopharma earnings beat revenue slowdown stock price movement